MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

Inicio・Lista de Acciones・Fate Therapeutics Inc

Fate Therapeutics Inc

Abierto

SectorSanidad

1.29 15.18

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.12

Máximo

1.29

Métricas clave
By Trading Economics
Ingresos	1.8M -32M
Ventas	-166K 1.7M
Margen de beneficios	-1,852.384
Empleados	181
EBITDA	7.9M -29M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+321.82% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	12M 137M
Apertura anterior	-13.89
Cierre anterior	1.29

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

325 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

0.9101 / 1.14 Soporte y Resistencia

Fate Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ene 2026, 23:49 UTC

Principales Movimientos del Mercado

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 ene 2026, 21:12 UTC

Principales Movimientos del Mercado

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 ene 2026, 20:29 UTC

Principales Movimientos del Mercado

Chip Makers Gain After Trump Calls Off European Tariffs

21 ene 2026, 20:04 UTC

Principales Movimientos del Mercado

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 ene 2026, 23:34 UTC

Charlas de Mercado

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 ene 2026, 22:39 UTC

Ganancias

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

21 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 ene 2026, 21:35 UTC

Adquisiciones, fusiones, absorciones

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 ene 2026, 21:19 UTC

Ganancias

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 ene 2026, 20:45 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 ene 2026, 20:36 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 ene 2026, 20:31 UTC

Charlas de Mercado

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 ene 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 ene 2026, 20:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 ene 2026, 20:27 UTC

Charlas de Mercado

Was It a 'TACO' Event? -- Market Talk

21 ene 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 ene 2026, 20:23 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 ene 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 ene 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Group Agrees to Buy Allfunds

21 ene 2026, 20:08 UTC

Ganancias

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 ene 2026, 20:03 UTC

Charlas de Mercado

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 ene 2026, 19:51 UTC

Charlas de Mercado

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 ene 2026, 19:43 UTC

Charlas de Mercado

U.S. Ethanol Production Expected to Slip -- Market Talk

21 ene 2026, 19:31 UTC

Charlas de Mercado

Gold Settles at Fresh All-Time High -- Market Talk

21 ene 2026, 19:24 UTC

Ganancias

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 ene 2026, 19:10 UTC

Charlas de Mercado

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 ene 2026, 18:57 UTC

Charlas de Mercado

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Comparación entre iguales

Cambio de precio

Fate Therapeutics Inc previsión

Precio Objetivo

By TipRanks

321.82% repunte

Estimación a 12 Meses

Media 4.64 USD 321.82%

Máximo 8 USD

Mínimo 2 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fate Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para Fate Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.9101 / 1.14Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentimiento

By Acuity

325 / 360 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.